@entity1 with end-stage @entity370 have now undergone lung transplantation successfully with good short-term and intermediate-term results. Lung transplantation for @entity370 requires several considerations unique to this disease. Selection of @entity10070 @entity1 for transplantation requires that medical therapy has been exhausted. This may involve the use of corticosteriods and alternative medications. Causes of @entity358 other than @entity10070 , such as @entity4595 and @entity296 , must be excluded before candidates are considered for transplantation. The extent and severity of @entity66 must also be assessed and may preclude lung transplantation. The presence of @entity13443 is considered a relative contra-indication by some transplant centres and an absolute contra-indication by others. Relatively few @entity1 with @entity10070 have undergone transplantation and, therefore, there are few data on outcome. @entity370 frequently recurs in the allograft, but rarely causes symptoms or @entity358 . More severe acute rejection episodes may occur in @entity370 transplant recipients, although at present there is no evidence of an increased risk of obliterative @entity5924 or increased mortality.

Lung transplantation for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial sarcoidosis'] @entity66 :: ('MESH:D004194', 'Disease') :: ['extrapulmonary disease'] @entity13443 :: ('MESH:D008271', 'Disease') :: ['mycetomas'] @entity5924 :: ('MESH:D001988', 'Disease') :: ['bronchiolitis'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary dysfunction'] @entity4595 :: ('MESH:D001987', 'Disease') :: ['bronchiectasis'] @entity370 :: ('MESH:D012507', 'Disease') :: ['sarcoidosis', 'Sarcoidosis'] @entity10070 :: ('MESH:D017565', 'Disease') :: ['pulmonary sarcoidosis']
@entity10070 :: (MESH:D017565,Disease) :: ['pulmonary sarcoidosis']
